E-mail a Wiley Online Library Link

D. Gonzalez, L. Fearfield, P. Nathan, P. Tanière, A. Wallace, E. Brown, C. Harwood, J. Marsden and S. Whittaker BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel British Journal of Dermatology 168

Version of Record online: 25 MAR 2013 | DOI: 10.1111/bjd.12248

What’s already known about this topic?

  •  Mutations in the BRAF gene have been identified as key drivers of melanoma cells and are found in around 50% of cutaneous melanomas.
  •  Vemurafenib (Zelboraf®) is the first licensed inhibitor of mutated BRAF and offers a new first-line option for patients with unresectable or metastatic melanoma who harbour BRAF mutations.
  •  Vemurafenib was developed in conjunction with a companion diagnostic, the cobas® 4800 BRAF V600 Mutation Test.

What does this study add?

  •  Evidence-based recommendations to facilitate the implementation of BRAF mutation testing and targeted therapy in patients with metastatic melanoma in the U.K.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field